For example, a single-institution matched case-control study in Japan demonstrated that adjuvant therapy with low-dose administration of IFNβ was beneficial for maintenance therapy in stage II and III melanoma patients without substantial toxic effects [42]. This evidence concerns the gene IFNB1 and melanoma.